A pilot study of 18 male patients has demonstrated an increase in hair density and thickness following botulinum toxin treatment.
Medical aesthetic company Evolus Inc has announced that the European Commission (EC) has approved the marketing of Nuceiva prabotulinumtoxinA (branded Jeuveau in the US and known in other markets as Nabota).
US-based medical aesthetic company Evolus Inc has begun a consumer campaign in the US called ‘#NEWTOX NOW’ in the hope to encourage patients to use its botulinum toxin.
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on the marketing authorisation application for Evolus’ botulinum toxin type A formulation.
The Food and Drug Administration (FDA) has approved Jeuveau, a botulinum toxin type A, for the temporary improvement in the appearance of moderate to severe glabellar lines.